haematuria; atonia; diarrhea; abdominal pain; vomiting; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. a 32 year-old female patient received bnt162b2 (comirnaty), administration date 24aug2021 (lot number: unknown) as dose 1, single and administration date 14sep2021 (batch/lot number: unknown) as dose 2, single for covid-19 immunisation. the patient had no relevant medical history. the patient's concomitant medications were not reported. the following information was reported: haematuria (disability, medically significant) with onset 29aug2021, outcome "not recovered", described as "haematuria"; hypotonia (disability, medically significant) with onset 29aug2021, outcome "not recovered", described as "atonia"; diarrhoea (disability, medically significant) with onset 29aug2021, outcome "not recovered", described as "diarrhea"; abdominal pain (disability, medically significant) with onset 29aug2021, outcome "not recovered", described as "abdominal pain"; vomiting (disability, medically significant) with onset 29aug2021, outcome "not recovered", described as "vomiting". clinical course: the patient during the first 4 days felt intense atonia, on day 5 she presented vomiting and intense abdominal pain (burning sensation). 2 days later started diarrhea. on 14sep2021 she received the second dose of comirnaty and the symptoms became more intense (diarrhea). 2 months later, after the second dose, she presented haematuria. now she was under medication. no medical history. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected